The Promise and Obstacle of p53 as a Cancer Therapeutic Agent

Author(s): A. C. Willis, X. Chen

Journal Name: Current Molecular Medicine

Volume 2 , Issue 4 , 2002

Become EABM
Become Reviewer
Call for Editor


p53 is a tumor suppressor gene that is mutated in greater than 50% of human cancers. The action of p53 as a tumor suppressor involves inhibition of cell proliferation through cell cycle arrest and / or apoptosis. Loss of p53 function therefore allows the uncontrolled proliferation associated with cancerous cells. While design of most anti-cancer agents has focused on targeting and inactivating cancer promoting targets, such as oncogenes, recent attention has been given to restoring the lost activity of tumor suppressor genes. Because the loss of p53 function is so prevalent in human cancer, this protein is an ideal candidate for such therapy. Several gene therapeutic strategies have been employed in the attempt to restore p53 function to cancerous cells. These approaches include introduction of wild-type p53 into cells with mutant p53 the use of small molecules to stabilize mutant p53 in a wild-type, active conformation and the introduction of agents to prevent degradation of p53 by proteins that normally target it. In addition, because mutant p53 has oncogenic gain of function activity, several approaches have been investigated to selectively target and kill cells harboring mutant p53. These include the introduction of mutant viruses that cause cell death only in cells with mutant p53 and the introduction of a gene that, in the absence of functional p53, produces a toxic product. Many obstacles remain to optimize these strategies for use in humans, but, despite these, restoration of p53 function is a promising anti-cancer therapeutic approach.

Keywords: p53, cancer therapy, garrest

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2002
Published on: 01 March, 2012
Page: [329 - 345]
Pages: 17
DOI: 10.2174/1566524023362474
Price: $65

Article Metrics

PDF: 1